Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo-Reference-Cited by-同舟云学术

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

Published:2017-05 Issue:5 Volume:76 Page:863-870
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Larsabal Maiana,Marti Aurélie,Jacquemin Clément,Rambert Jérôme,Thiolat Denis,Dousset Léa,Taieb Alain,Dutriaux Caroline,Prey Sorilla,Boniface Katia,Seneschal Julien

Publisher

Elsevier BV

Subject

Dermatology

Reference20 articles.

1. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

5. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab;Hua;JAMA Dermatol,2016

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study;BMC Cancer;2024-06-14

2. Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors;Russian Journal of Skin and Venereal Diseases;2024-05-14

4. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity – a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital;Clinical and Experimental Dermatology;2024-02-19

5. Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center;Current Oncology;2024-02-19